memantine

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Aphasia

Conditions

Aphasia, Stroke

Trial Timeline

Mar 1, 2005 → Sep 1, 2005

NCT ID

NCT00196703

About memantine

memantine is a approved stage product being developed by Lundbeck for Aphasia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00196703. Target conditions include Aphasia, Stroke.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00800709	Approved	Completed	Jul 1, 2008	Oct 1, 2010	Alzheimer's Disease
NCT00703430	Pre-clinical	UNKNOWN	Mar 1, 2008	Jun 1, 2014	Alzheimer's Disease
NCT00401167	Approved	Completed	Nov 1, 2006	Jan 1, 2010	Alzheimer's Disease
NCT00196703	Approved	UNKNOWN	Mar 1, 2005	Sep 1, 2005	Aphasia
NCT00857233	Phase 3	Terminated	Jun 1, 2004	Oct 1, 2010	Alzheimer's Disease

Competing Products

3 competing products in Aphasia

See all competitors

Product	Company	Stage	Hype Score
Wait first, then levetiracetam + Levetiracetam first, then wait	UCB	Phase 1	30
memantine + memantine + placebo	Lundbeck	Approved	82
Neflamapimod + Placebo	CervoMed	Phase 2	44

Other Products from Lundbeck

VortioxetineApproved

memantine + memantine + placeboApproved

escitalopram + escitalopramApproved

BrexpiprazoleApproved

losartan (drug)Approved